Cargando…

Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!

Detalles Bibliográficos
Autores principales:	Luherne, Camille, Darrigade, Anne-Sophie, Dutriaux, Caroline, Prey, Sorilla, Milpied, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Notes & Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488678/ https://www.ncbi.nlm.nih.gov/pubmed/31061867 http://dx.doi.org/10.1016/j.jdcr.2019.02.033

Ejemplares similares

Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib
por: Pinard, Camille, et al.
Publicado: (2017)

Vemurafenib and Dabrafenib Downregulates RIPK4 Level
por: Madej, Ewelina, et al.
Publicado: (2023)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
por: Daud, Adil, et al.
Publicado: (2017)

The unexpected always happens
por: Jobling, Mark A
Publicado: (2012)

Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
por: Mistry, Hitesh B., et al.
Publicado: (2017)

Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma
por: Tahseen, Ahmed I., et al.
Publicado: (2018)

Response to low-dose intravenous immunoglobulin in a case of recalcitrant Darier disease
por: Legrand, Adeline, et al.
Publicado: (2020)

Boosters appear effective, but are they always needed?
por: Reddy, K Srinath
Publicado: (2021)

Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
por: Orouji, Elias, et al.
Publicado: (2014)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
por: Ghezzi, Marco, et al.
Publicado: (2020)

Is electrosynthesis always green and advantageous compared to traditional methods?
por: Yuan, Yong, et al.
Publicado: (2020)

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
por: Ascierto, Paolo A, et al.
Publicado: (2015)

Does family always matter? Public genomes and their effect on relatives
por: Bloss, Cinnamon S
Publicado: (2013)

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
por: Valentin, Julie, et al.
Publicado: (2021)

Mini Safe Havens for population recovery and reintroductions ‘beyond-the-fence’
por: Smith, Kiarrah J., et al.
Publicado: (2022)

Reintroduction of the invasive mosquito species Aedes albopictus in Belgium in July 2013
por: Boukraa, Slimane, et al.
Publicado: (2013)

Ecstasy‐induced fixed drug eruption
por: Barbier, Ophélie, et al.
Publicado: (2022)

Reintroduction
por: Bindenagel Šehović, Annamarie
Publicado: (2017)

Open questions: knowing who’s who in multicellular animals is not always as simple as we imagine
por: Weiss, Robin A.
Publicado: (2018)

The right ventricle: always normal in normal subjects?
por: van der Wall, E. E.
Publicado: (2014)

Keratinocyte junctions and the epidermal barrier: how to make a skin-tight dress
por: Bazzoni, Gianfranco, et al.
Publicado: (2002)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study
por: Dousset, Léa, et al.
Publicado: (2021)

Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as “toxic epidermal necrolysis-like”
por: Eldani, Céline, et al.
Publicado: (2023)

Safely meeting global salmon demand
por: Smejkal, Gary B., et al.
Publicado: (2018)

Are COVID-19 vaccines safe in pregnancy?
por: Male, Victoria
Publicado: (2021)

Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox
por: Robak, Tadeusz, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
por: Gao, Tianfu, et al.
Publicado: (2021)

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
por: Ladouceur, Alexandra, et al.
Publicado: (2023)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

Comment on Hogas et al. Salt, Not Always a Cardiovascular Enemy? A Mini-Review and Modern Perspective. Medicina 2022, 58, 1175
por: Campbell, Norm R. C., et al.
Publicado: (2022)

Loss of autophagy affects melanoma development in a manner dependent on PTEN status
por: Rosenfeldt, Mathias T., et al.
Publicado: (2021)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Ushering in safe, effective, secure, and ethical medicine in the digital era
por: Gordon, William J., et al.
Publicado: (2021)

Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2022)

Antiseptic Surgical Dressing
Publicado: (1898)

Sputnik V COVID-19 vaccine candidate appears safe and effective
por: Jones, Ian, et al.
Publicado: (2021)

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era
por: Boaventura, Viviane S, et al.
Publicado: (2023)

Science surrounding the safe use of bioactive ingredients in infant formula: federal comment
por: Vargas, Ashley J., et al.
Publicado: (2023)

A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma
por: LUHERNE, Camille, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uunmq4a2kqfsa2dk16fq97enp2